( s important that SPP100 leads to additi...)New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension,Health

Summary of posters presented by investigators 19-22 May 2007 at the 22nd Annual Scientific Meeting and Exposition of the American Society of Hypertension (ASH) in Chicago, IL, USA

Aliskiren-based therapy provides long-term suppression of plasma renin activity that persists after stopping therapy in patients with hypertension Myron H Weinberger, Karl Andersen, Christian M Constance, Mohammed A Ali, James Jin, Margaret F Prescott; Poster P-445

* Aliskiren-based therapy produced effective control of blood pressure and plasma renin activity over 6 months. * Significant reductions of plasma renin activity persisted 4 weeks after stopping aliskiren treatment in parallel with sustained blood pressure reductions, suggesting that aliskiren has continued inhibitory effects on the renin system beyond its plasma elimination half-life.

Aliskiren-based therapy provides long-term renin system suppression in patients with hypertension in a 52-wk comparator trial with hydrochlorothiazide-based therapy T Philipp, RE Schmieder, J Guerediaga, M Gorostidi, B Smith, M Maboudian, J Botha, MF Prescott; Poster P-421

* Aliskiren-based therapy provided reductions of plasma renin activity that were maintained during long-term (12 months) treatment in patients with mild-to moderate essential hypertension.

The direct renin inhibitor aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in patients with hypertension S Oparil, SA Yarows, S Patel, H Fang, J Zhang, A Satlin; Poster P-418

* Dual renin system intervention with the combination of aliskiren and valsartan provides clinically significant additional blood pressure reductions and improved blood pressure control, with tolerability similar to that of the individual monotherapies.

Aliskiren in co
'"/>